Fig. 1 · Structure

Documents & Downloads

Selumetinib (AZD6244)

Cat. No. A10257 CAS 606143-52-6

MEK inhibitor

AZD6244 (Selumetinib) also known as Selumetinib, ARRY142886, AZD-6244 & ARRY-142886 is MEK 1/2 inhibitor with GI50 values ranging from 14 to 50 nm.

In Stock

Publications for Selumetinib

1 publication citing this product

  1. Chia-Chi Chang, .et al. , Oncotarget, 2016, Jun 7; 7(23): 35270-35283 PMID: 27150057

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

In 14-3-3ζ-overexpressing mammary epithelial cells, selumetinib reduced ERK and CREB phosphorylation and LDHA expression, supporting an effect on the MEK–ERK–CREB pathway. This experiment does not establish direct inhibition of LDHA. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
MEK1 (Cell-free assay) 14 nM

Cellular Effect

Cell Line Activity Value Description Reference
A-375 IC50 31 nM Antiproliferative activity against human A375 cells expressing BRAF V600E mutant after 72 hrs by Cell titer-glo assay [PMID: 23474388]
A549 IC50 > 100 μM Antiproliferative activity against human A549 cells after 48 hrs by MTT assay [PMID: 30777660]
ASPC1 IC50 64.2 nM Antiproliferative activity against human AsPC1 cells harboring KRAS G12D mutant after 72 hrs by CellTiter-Glo assay [PMID: 28038940]
BaF3 IC50 > 1 x 10 Antiproliferative activity against mouse BA/F3 cells harboring KRAS G12D mutant after 72 hrs in presence of IL-3 by CellTiter-Glo assay [PMID: 28038940]
BaF3 IC50 100 nM Antiproliferative activity against mouse BA/F3 cells harboring KRAS G12D mutant after 72 hrs by CellTiter-Glo assay [PMID: 28038940]
COLO 205 IC50 59 nM Antiproliferative activity against human COLO205 cells harboring BRAF mutant/wild type KRAS/wild type PIK3CA after 72 hrs by CCK8 assay [PMID: 29317148]
DLD-1 IC50 1.25 μM Anticancer activity against human DLD-1 cells assessed as reduction in cell viability incubated for 24 hrs by Cell Titer-Glo assay [PMID: 33445154]
HCT-116 IC50 0.95 μM Anticancer activity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by Cell Titer-Glo assay [PMID: 33445154]
PANC-1 IC50 > 1 x 10 Antiproliferative activity against human PANC1 cells harboring KRAS G12D mutant after 72 hrs by CellTiter-Glo assay [PMID: 28038940]
SK-CO-1 IC50 117 nM Antiproliferative activity against human SKCO1 cells harboring KRAS G12V mutant after 72 hrs by CellTiter-Glo assay [PMID: 28038940]
SW480 IC50 0.422 μM Antiproliferative activity against human SW480 cells after 72 hrs by MTT assay [PMID: 27448918]
SW-620 IC50 15 nM Antiproliferative activity against human SW620 cells harboring KRAS G12V mutant after 72 hrs by CellTiter-Glo assay [PMID: 28038940]

12 records · Scroll to view more

In Vitro Studies

AZD6244 at 10 μM reduced LDHA protein and mRNA in MCF10A and MCF12A sublines overexpressing 14-3-3ζ relative to DMSO. The shared inhibitor methods specify at least 5 hours of exposure; this is a treatment concentration, not an IC50. [1]

ERK–CREB–LDHA response in mammary epithelial cells

Cell-based study · MCF10A and MCF12A sublines overexpressing 14-3-3ζ, with matched empty-vector sublines [1]

AZD6244 reduced phospho-ERK, phospho-CREB and LDHA expression, including LDHA mRNA, in the 14-3-3ζ-overexpressing sublines compared with DMSO. Total ERK, CREB and β-actin are displayed as controls. This pathway perturbation does not demonstrate direct LDHA inhibition.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Phospho-ERK1/2, phospho-CREB Ser-133, LDHA protein and LDHA mRNADirection of change Reduced versus DMSO in 14-3-3ζ-overexpressing sublines[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 μM
Exposure duration
At least 5 hours before lysate collection
Method
Cell treatment; immunoblotting and qRT-PCR normalized to 18S rRNA
Vehicle
DMSO
Reported limits
Exact duration for each Figure 4 endpoint, DMSO percentage and biological replicate number are not specified in the adopted caption/shared inhibitor methods. No IC50 was measured here.
Methods and source locations

Compound reported in the paper: Selumetinib; Compound label in the paper: AZD6244

Compound-level relevance; does not validate an Adooq lot or establish supplier-specific performance or salt equivalence.

Figure 4E–F; Results: transcriptional up-regulation of LDHA; Methods: chemical inhibitors and qRT-PCR

Phospho-ERK1/2, phospho-CREB Ser-133, LDHA protein and LDHA mRNA: Immunoblotting (Figure 4E); qRT-PCR (Figure 4F) — Figure 4E–F and corresponding Results paragraph

In Vivo Studies

In a DCIS-like mouse xenograft study, daily oral AZD6244 (16 mg/kg) produced reported growth inhibition >75% in 14-3-3ζ-overexpressing tumors and <50% in empty-vector tumors versus their respective vehicle controls (5 mice/group). These are model-specific growth effects. [1]

Responses varied across pediatric xenografts. The primary PPTP panel had no objective responses, and deaths occurred in 11/428 treated mice versus 0/420 controls. In subsequent astrocytoma tests, BT-40 tumors (BRAF V600E) completely regressed during treatment, whereas BT-35 tumors (BRAF wild type) progressed; BT-40 regrowth followed withdrawal. [2]

DCIS-like mammary xenograft growth

Animal study · MCF10DCIS.COM.ζ and empty-vector DCIS.COM.Vec orthotopic mammary tumors in 6-week-old female SWISS nu/nu mice [1]

Daily AZD6244 inhibited growth of both tumor variants, with a larger reported inhibition in 14-3-3ζ-overexpressing tumors. The Ki-67 reduction was significant in the ζ tumors; the vector comparison was not marked significant. Groups contained 5 mice.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tumor growth versus respective vehicle-treated modelReported tumor growth inhibition >75% for DCIS.COM.ζ; <50% for DCIS.COM.Vec[1]

Conditions shared by the study groups

Route
Oral gavage
Frequency
Daily
Treatment course
Day 10 to day 30 after implantation; 20 days after treatment initiation
Vehicle
0.5% HPMC, 0.1% Tween 80 in 25 mM citrate
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
14-3-3ζ-overexpressing tumors
16 mg/kg body weight
Same-model vehicle group; n=5 mice per groupReported tumor growth inhibition >75%; reduced Ki-67 positivity versus vehicle[1]
Empty-vector tumors
16 mg/kg body weight
Same-model vehicle group; n=5 mice per groupReported tumor growth inhibition <50%; Figure 5D vector Ki-67 comparison is not marked significant[1]
14-3-3ζ-overexpressing tumors
Model: DCIS.COM.ζ mammary xenografts
Reported limits: No per-experiment vendor/lot; salt unspecified.
Empty-vector tumors
Model: DCIS.COM.Vec mammary xenografts
Reported limits: No per-experiment vendor/lot; salt unspecified.
Methods and source locations

Compound reported in the paper: Selumetinib; Compound label in the paper: AZD6244

Compound-level relevance; does not validate an Adooq lot or establish supplier-specific performance or salt equivalence.

Figure 5A–D; Results: targeting MEK/ERK/CREB; Methods: tumor xenograft studies

Tumor growth versus respective vehicle-treated model: Serial caliper measurements; relative tumor volume — Results: targeting MEK/ERK/CREB paragraph corresponding to Figure 5B

14-3-3ζ-overexpressing tumors · Figure 5A–D; corresponding Results; tumor xenograft methods

Empty-vector tumors · Figure 5A–D; corresponding Results; tumor xenograft methods

Limited responses in the primary pediatric xenograft panel

Animal study · Primary PPTP panel: 44 xenograft models tested; 43 evaluable after exclusion of ALL-17 for >25% toxicity [2]

No objective responses (defined in the main text as ≥50% tumor-volume regression) were reported. Ten of 43 evaluable models had significant EFS-distribution differences. Eleven of 428 treated mice died versus 0 of 420 controls; one model was excluded for toxicity. P values were exploratory and unadjusted for multiple comparisons.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Objective response in primary evaluable panelObjective responses None[2]
Deaths during primary panel studyDeaths / mice 11/428 (2.6%) treated; 0/420 (0%) control[2]

Conditions shared by the study groups

Route
Oral (p.o.)
Frequency
Twice daily Monday–Friday; once daily Saturday–Sunday
Treatment course
6 consecutive weeks
Vehicle
0.5% hydroxypropyl methyl cellulose, 0.1% Polysorbate 80
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Primary panel AZD6244
100 mg/kg
Control groups in main panel; vehicles defined under Drugs and FormulationNo objective responses; best group response was progressive disease with growth delay in nine models[2]
Primary panel AZD6244
Model: PPTP primary xenograft panel; 10 mice/group for solid tumors and 8/group for ALL, before exclusions
Reported limits: Detailed schedule conflicts with simplified abstract; supplemental response definitions and full exclusion table were not retrieved.
Methods and source locations

Compound reported in the paper: Selumetinib; Compound label in the paper: AZD6244

Research compound evidence; no Adooq material validation or conversion to a sulfate formulation.

Results: in vivo testing; Table II; Figure 2; Drugs and Formulation; Figure 3 caption

Objective response in primary evaluable panel: Main Results define objective responses as ≥50% tumor-volume regression; Figure 2 group response classification — Results: in vivo testing; Figure 2

Deaths during primary panel study: Author-reported deaths during study; not assumed all drug-caused — Results: in vivo testing opening paragraph

Primary panel AZD6244 · Drugs and Formulation; Figure 3 caption; Results in vivo testing; Figure 2

Contrasting responses of BT-35 and BT-40 astrocytoma xenografts

Animal study · BT-35 (BRAF wild type) and BT-40 (BRAF V600E) juvenile pilocytic astrocytoma xenografts [2]

BT-40 showed complete regressions at the end of six weeks across the reported schedules, whereas BT-35 progressed. Regrowth after treatment withdrawal depended on cumulative exposure. These two models do not establish BRAF genotype as a sufficient predictor across cancers.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
End-of-treatment tumor responseReported categorical response BT-40: complete regressions; BT-35: progression[2]

Conditions shared by the study groups

Route
Oral (p.o.)
Frequency
Twice daily Monday–Friday; once daily Saturday–Sunday
Treatment course
6 consecutive weeks
Vehicle
0.5% hydroxypropyl methyl cellulose, 0.1% Polysorbate 80
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
BT-35 comparator
100 mg/kg
Untreated control curves shown in Figure 7; common formulation methods report vehicleTumors progressed despite AZD6244 treatment[2]
BT-40 responsive model
100 mg/kg
Untreated control curves shown in Figure 7; common formulation methods report vehicleComplete regressions reported at six weeks; regrowth occurred after cessation[2]
BT-35 comparator
Model: BT-35; BRAF wild type
Reported limits: Secondary cohort-specific n and exclusions not retrieved; genotype comparison is between different tumor models, not an isogenic test.
BT-40 responsive model
Model: BT-40; BRAF V600E
Reported limits: Secondary cohort-specific n and exclusions not retrieved; genotype comparison is between different tumor models, not an isogenic test.
Methods and source locations

Compound reported in the paper: Selumetinib; Compound label in the paper: AZD6244

Research compound evidence; no Adooq material validation or conversion to a sulfate formulation.

Results: JPA xenografts; Figure 7A–B and caption; Drugs and Formulation

End-of-treatment tumor response: Tumor-volume trajectories and author-reported response — JPA Results and Figure 7A–B

BT-35 comparator · Figure 7A–B and caption; JPA Results; Drugs and Formulation

BT-40 responsive model · Figure 7A–B and caption; JPA Results; Drugs and Formulation

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 606143-52-6
Applications MEK inhibitor
Formula C17H15BrClFN4O3
Molecular Weight 457.7
Synonyms ARRY-142886; AZD6244
SMILES
CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)Cl)C(=O)NOCCO

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Warmed: 80 mg/mL (174.79 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
4 mg/mL
Vehicle
4% DMSO+30% PEG 300+5% Tween 80+ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Chang CC, Zhang C, Zhang Q, et al. Upregulation of lactate dehydrogenase a by 14-3-3ζ leads to increased glycolysis critical for breast cancer initiation and progression. Oncotarget (2016). PMID: 27150057 DOI: 10.18632/oncotarget.9136 Source material
  2. [2] Kolb EA, Gorlick R, Houghton PJ, et al. Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program. Pediatric blood & cancer (2010). PMID: 20806365 DOI: 10.1002/pbc.22576 Source material

Publications

1 publication citing this product

  1. Chia-Chi Chang, .et al. , Oncotarget, 2016, Jun 7; 7(23): 35270-35283 PMID: 27150057

Added to your cart

View Cart Checkout
Loading...